It is well known that herpes zoster infections occur with greater frequency in immunocompromised patients. ' Since the first description of HTLV-III infection in Rwanda in 1984,2 the number of cases of herpes zoster ophthalmicus (HZO) seen in our ophthalmology department at the Centre Hospitalier de Kigali has been steadily increasing. The purpose of the present study was twofold. First we wanted to determine whether there is a relationship between this increasing frequency of HZO and the presence of HTLV-III in the population. Secondly we wanted to document the degree of eye damage caused by this herpetic infection.
Material and methods
All patients with HZO followed up All other patients received a combination of cycloplegic drugs (atropine 1%) and oxytetracycline 1% and hydrocortisone 0-5% ointment. The atropine was prescribed twice daily until flare and cells had completely disappeared. The ointment was prescribed from twice to six times daily depending on the severity of the ocular involvement, and it was continued until the eye became white. Fundus lesions which we considered to be unrelated to the actual attack of herpes zoster were observed in six patients. The fundus of the right eye (contralateral to the herpes zoster infection) of patient 2 showed a heavy perivasculitis of the peripheral vessels and a moderate degree of vitreous flare. Five other patients (cases 6, 11, 13, 17, and 18) had bilateral perivasculitis of the peripheral retinal vessels, varying from a discrete perivascular sheathing to a frank perivascular infiltrate.
Discussion
The most striking finding in this study is that all our patients with HZO are HTLV-III seropositive. This statistically highly significant association amply confirms our clinical impression that there is a relationship between the rising number of cases of HZO and the advent of HTLV-III infections in Rwanda. As already suggested by Cole and coworkers,5 acquired immune deficiency syndrome (AIDS) should be considered in young, healthy persons with HZO and no known cause of immunosuppression. They described HZO in four patients, two with AIDS and two with the AIDS related complex. Our series of HZO adds an important aspect to their observation: HZO is not only a manifestation seen in patients with AIDS or AIDS-related complex, but also a marker for HTLV-III seropositivity in healthy carriers. Indeed 17 of 19 seropositive patients with HZO (89.4%) affirmed themselves to be in good health. They had no lymphadenopathy and they did not complain of weight loss, fatigue, night sweats, or diarrhoea. The clinical features of herpes zoster ophthalmicus in HTLV-III positive patients are somewhat different from the classical picture of this disease. In our opinion two distinct differences should be stressed. First, the peak incidence of HTLV-III related HZO is situated in a young age group (third decade), and, secondly, the disease tends to run a more severe course in HTLV-III positive patients in terms of corneal involvement and postzonal pain. Table 2 illustrates these differences by comparing selected clinical features of our We believe from the present study that the laboratory investigation of patients with herpes zoster should include a determination of antibodies against HTLV-III in areas where this virus is endemic or in patients with known risk factors. The presence of a perivasculitis or perivascular sheathing of the peripheral fundus vessels in both eyes may already give a clue to the presence of HTLV-III infection in a case of HZO. We described this finding in patients with AIDS and AIDS-related complex, both in children and in adults,89 and observed it in five patients of the present series. The ophthalmologist should inform the seropositive patient that he is a potential source of infection for his sexual partners and refer him to a venereologist for further counselling on this subject.
The high percentage of corneal involvement with subsequent visual loss and of postzonal neuralgia in this group of patients seems to justify the routine use of intravenous acyclovir, the current treatment of choice for zoster infections in immunocompromised patients."' Unfortunately this treatment is far too expensive for routine use in a developing country. In our patients we were reluctant to give large doses of steroids for several reasons. Systemic treatment with steroids, advocated for severe cases of HZO and postherpetic neuralgia," 2 is in our opinion contraindicated in HTLV-III seropositive patients, especially in Africa, where follow-up is less than optimal and where complications of systemic steroid treatment may cause more harm than the loss of visual acuity in one eye. Topical prednisone treatment should be used sparingly in the presence of epithelial disease,4 and a high number of our HTLV-III seropositive patients presented with early pseudodendrites and punctate epithelial keratitis (see Table  1 ), indicating active viral replication with the corneal epithelium. Although we agree that the visual outcome in some of our cases was negatively influenced by the withholding of potent topical steroids, it should be kept in mind that, once instituted, steroids need to be given over a long period, as later recrudescences are especially common after corticosteroid withdrawal. This means placing a heavy financial burden on our mostly poor patients.
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